Latest »
Sixth Closed Scientific Expert Meeting of the Editorial Board
Insights into apoC3’s mechanism of action
Karin Bornfeldt, University of Washington, Seattle, USA, reviews research supporting a link between elevated apoC3 and increased risk of coronary artery disease in people with type 1 diabetes and the evidence that this elevation is partly due to relative insulin deficiency and/or hepatic insulin resistance. She also considers the potential of apoC3 silencing in preventing atherosclerosis progression.Watch presentation >
What is your choice of therapeutic target for TG lowering? The cardiologist’s viewpoint
David Hare, University of Melbourne, Australia, offers a cardiologist’s perspective on the importance of triglyceride as a cardiovascular risk factor and the evidence supporting different options for triglyceride lowering, including dietary modification, intensification of LDL lowering, and the use of fibrates and omega-3 fatty acids.Watch presentation >
What is your choice of therapeutic target for TG lowering? The endocrinologist’s viewpoint
Klaus Parhofer, University of Munich, Germany, explains how endocrinologists estimate risk of atherosclerotic cardiovascular disease and pancreatitis based on triglyceride and other lipid/non-lipid risk factors, eliminate secondary causes of hypertriglyceridaemia, and use lifestyle modification, statins, fibrates, and high dose omega-3 fatty acids.Watch presentation >
Expert commentaries
Growing evidence supports use of remnant cholesterol in ASCVD risk classification
Elevated remnant cholesterol has consistently been linked to increased risk of cardiovascular (CV) events, so should it be added to CV risk scores to help identify patients most in need of primary or secondary prevention? Professor Børge G. Nordestgaard discusses the evidence, and the implications for treatment decisions.
New APOC3 loss-of-function data support apoCIII as a treatment target for CV disease prevention
Professor Marja-Riitta Taskinen reviews new APOC3 loss-of-function research aimed at gaining a better understanding of the regulatory role of apoCIII and its potential in atherosclerotic cardiovascular disease prevention.
Read the commentary
Third Closed Scientific Expert Meeting of the Editorial Board
Keynote: What have we learned from triglyceride lowering trials using fibrates over the past 40 years?
Professor Marja-Riitta Taskinen reviews the evidence from the FIELD and ACCORD clinical trials in type 2 diabetes and considers how treatment might be tailored to patients most likely to benefit.
Novel PPAR agonists as therapeutics in hypertriglyceridaemia
Professor Bart Staels discusses latest understanding of the mechanisms of action of PPAR agonists, together with pre-clinical and clinical data on the selective PPARα modulator, pemafibrate.
Expert Commentaries
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
Professor Gary Lewis (University of Toronto, Canada) discusses the evidence presented in the 2021 EAS Consensus Statement and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller (University of Maryland, Baltimore, USA) discusses the background to the latest ACC guidance and the recommendation to stratify patients for treatment according to their residual LDL-cholesterol level.
Clinical trials of innovative therapeutics
New insights into the biology of triglyceride metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and, for severely elevated levels, pancreatitis.
In the last decade epidemiology and genetic studies – in particular, Mendelian randomisation studies – have moved the field forward and we are on the cusp of a new era in managing elevated triglycerides.
Major outcomes studies with these new therapies are fundamental to answering the much-debated question: Does lowering elevated triglycerides reduce residual cardiovascular risk?
About Triglyceride Forum
The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis. This Forum will provide clinicians and researchers with international, open access, peer-reviewed resources at an important time when new and innovative molecules are at advanced stages of development… Read more >>
Why join?
Professors Ginsberg and Chapman explain the fundamental scientific and clinical research that has turned the spotlight on triglyceride-rich lipoproteins and their remnants as important players in the development of atherosclerotic CVD and pancreatitis and as targets for novel therapies for both these serious diseases.
FREE MEMBERSHIP
Join the Triglyceride Forum for open access to independent, evidence based knowledge and high quality educational programmes
View invitation from Henry Ginsberg
Join the Triglyceride Forum to share new data and exchange opinions with clinicians and researchers around the world
View invitation from John Chapman
Meet our Steering Committee
MAKING THE CONNECTION: TRIGLYCERIDES, RESIDUAL CV RISK AND PANCREATITIS
This unique, downloadable slide deck developed specially for Triglyceride Forum is a state-of-the-art guide to triglycerides and their association with residual cardiovascular risk and pancreatitis.
Why triglycerides now?
From the editors
Educational partners and supporters
